

5367,230-US
October 22, 2004

Application Number 10/730,215
Page 6 of 7

REMARKS

In response to the restriction requirement set forth in the Office Action of September 29, 2004, Applicants hereby elect, Group 8 (listed in the Office Action as original claims 4-5 and 10-11 (in part)), for further prosecution (as modified by the claim amendments provided herein).

In response to the election of species request, Applicants hereby elect methods comprising administration of a non-naturally occurring polypeptide having the amino acid sequence His Gly Asp Gly Ser Phe Ser Asp Gly Met Asn Thr Ile Leu Asp Asn Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu le Gln Thr Lys Ile Thr Asp (corresponding to a variant of human native GLP-2 (1-33), characterized by substitution of Ala₂ with a Gly residue) or a composition comprising the same, *in the event that no generic claims are found allowable*. All of the presently pending claims are readable on the elected species.

Claims 1-3 and 6-9 are hereby cancelled, without prejudice, to bring the claims into consonance with the elections made herein. Claims 4-5 and 10-11 are amended for similar reasons. Applicants reserve the right to pursue claims similar to the original claims in this or related applications at a later time. New claims 12-15 are directed to additional particular aspects of Applicants' invention which are supported by the specification. No new matter is added.


It is respectfully submitted that the elected claims are in condition for allowance. Early action to that end is respectfully requested. The Commissioner is hereby authorized to charge any fees in connection with

5367,230-US
October 22, 2004

Application Number 10/730,215
Page 7 of 7

this application and to credit any overpayments to Deposit Account No. 14-1447. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution and allowance of this application, the Examiner is hereby invited to call the undersigned attorney.

Respectfully submitted,



Date: October 22, 2004

Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800